SCHEMBL23574356

SCHEMBL23574356

CS(=O)(=O)OCC(COCc1ccccc1)COS(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
CA1 P00915 6/20 0.44
CA2 P00918 4/20 0.44
CA9 Q16790 4/20 0.44
CA7 P43166 3/20 0.44
TACR1 P25103 2/20 0.42
SLC1A1 P43005 1/20 0.41
CA4 P22748 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
NPC1 O15118 1/20 0.39
AR P10275 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26096274 0.86 CA1 (0.42) TSHRCA1CA2CA9CA7
SCHEMBL9276273 0.85 TSHR (0.44) TSHRCA1CA2CA9CA7
SCHEMBL9613931 0.83 KMT2A (0.43) TSHRCA1CA2CA9CA7
SCHEMBL11033646 0.83 TSHR (0.41) TSHRCA1CA2CA9CA7
SCHEMBL21848157 0.82 TSHR (0.67) TSHRCA1CA2CA9CA7
SCHEMBL29096794 0.81 SLC1A1 (0.57) TSHRCA1CA2CA9CA7
SCHEMBL9511215 0.81 CA1 (0.42) TSHRCA1CA2CA9CA7
SCHEMBL30741856 0.81 CA2 (0.45) TSHRCA1CA2CA9CA7
SCHEMBL27571883 0.80 TSHR (0.60) TSHRCA1CA2CA9CA7
SCHEMBL9613908 0.80 CA1 (0.39) TSHRCA1CA2CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371982-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2024-05-22 EP disclosed
EP-3583096-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-03-27 EP disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC TSHR 4174/4885CA1 4337/4885CA2 4501/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC TSHR 4174/4885CA1 4337/4885CA2 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.